



1 to medication, or causing a forced switch to a medication not prescribed by the patient's  
2 doctor; and

3 WHEREAS, it is important for Louisiana to ensure that patient assistance programs  
4 remain sustainable and available to support the population for which they are intended.

5 THEREFORE, BE IT RESOLVED that the Legislature of Louisiana does hereby  
6 authorize and request the Department of Insurance to create the Louisiana Alternative  
7 Funding Program Task Force to study the impact of alternative funding programs on patient  
8 access to affordable prescription drugs.

9 BE IT FURTHER RESOLVED that the Louisiana Alternative Funding Program Task  
10 Force shall be comprised of the following members:

- 11 (1) The commissioner of insurance.
- 12 (2) The chief executive officer of the Louisiana State Medical Society.
- 13 (3) The executive director of the Louisiana Oncology Society.
- 14 (4) The president of the Rheumatology Alliance of Louisiana.
- 15 (5) The executive director of the Coalition of State Rheumatology Organizations.
- 16 (6) The chief executive officer of the Louisiana Association of Health Plans.
- 17 (7) The president of Health Agents for America.
- 18 (8) The president of the Pharmaceutical Care Management Association.
- 19 (9) The chief executive officer of Pharmaceutical Research and Manufacturers of  
20 America.
- 21 (10) The chief executive officer of the Louisiana Independent Pharmacies  
22 Association.

23 BE IT FURTHER RESOLVED that the Louisiana Alternative Funding Program Task  
24 Force shall study all of the following:

- 25 (1) The history and prevalence of alternative funding programs in the United States  
26 and Louisiana, including but not limited to the types of health insurance products that utilize,  
27 all or in part, alternative funding programs to provide access, coverage, or discounts for  
28 prescription drugs.
- 29 (2) The business model of alternative funding programs.

1           (3) The impact of alternative funding programs on patient assistance programs for  
2 prescription medications, including but not limited to long-term stability of those patient  
3 assistance programs if an upswing in alternative funding programs is realized across an  
4 increased number of health insurance products.

5           (4) The impact of alternative funding programs on coverage of prescription  
6 medications if the utilization of alternative funding programs is expanded across additional  
7 insurance products, including but not limited to commercial health coverage plans, health  
8 coverage plans offered to public employees, and health coverage plans offered to individuals  
9 in the state's health insurance exchange.

10           BE IT FURTHER RESOLVED that the commissioner of insurance shall serve as the  
11 chairman of the task force and the staff of the Department of Insurance shall provide support  
12 to the task force.

13           BE IT FURTHER RESOLVED that each appointed member of the task force may  
14 appoint a designee who shall serve on the task force on his behalf.

15           BE IT FURTHER RESOLVED that the members of the task force shall serve  
16 without compensation, except per diem or expense reimbursement to which they may be  
17 individually entitled as members of their constituent organizations.

18           BE IT FURTHER RESOLVED that a majority of the total membership shall  
19 constitute a quorum of the task force, and any official action by the task force shall require  
20 an affirmative vote of a majority of the quorum present and voting.

21           BE IT FURTHER RESOLVED that the names of the members designated in this  
22 Resolution shall be submitted to the chairman of the task force by July 15, 2024, and the  
23 chairman shall thereafter call the first meeting of the task force by August 15, 2024.

24           BE IT FURTHER RESOLVED that the task force shall meet as necessary and  
25 provide a written report of its findings from the study, together with any recommendations  
26 for legislation, to the House Committee on Insurance, the Senate Committee on Insurance,  
27 and the David R. Poynter Legislative Research Library no later than December 31, 2024.

28           BE IT FURTHER RESOLVED that the task force shall terminate upon the date of  
29 submission of its report.

1 BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the  
 2 commissioner of insurance, the chief executive officer of the Louisiana State Medical  
 3 Society, the executive director of the Louisiana Oncology Society, the president of the  
 4 Rheumatology Alliance of Louisiana, the executive director of the Coalition of State  
 5 Rheumatology Organizations, the chief executive officer of the Louisiana Association of  
 6 Health Plans, the president of Health Agents for America, the president of the  
 7 Pharmaceutical Care Management Association, the chief executive officer of Pharmaceutical  
 8 Research and Manufacturers of America, and the chief executive officer of the Louisiana  
 9 Independent Pharmacies Association.

---

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

---

HCR 96 Original

2024 Regular Session

Brown

Creates the La. Alternative Funding Program Task Force to study and make recommendations regarding the impact of alternative funding programs on patient access to affordable prescription drugs.

Specifies the members of the task force and provides that members serve without compensation, except for such reimbursement or per diem they are individually entitled to as members of the constituent groups they represent.

Requests the task force to report its findings, with any recommendations for legislation, no later than Dec. 1, 2024.